Findings

What do systematic reviews say?

9 questions · 9 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 33.3%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 3 · 33.3%Moderate 0 · 0%High 1 · 11.1%

Inotersen vs placebo

QoL · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 172 participants
Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

Mean quality of life ‐ health utility · adults with acute spontaneous intracerebral haemorrhage

1 finding from 1 review

Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2349 participants
High

Intervention not reported

Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Biological therapy vs placebo, best supportive care (BSC) or no treatment

QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 283 participants
Low

Chemmotherapy combined with biological therapy vs chemotherapy alone

QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).

1 finding from 1 review

Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
HR 0.88 [0.74, 1.04]
2 studies · 1154 participants
Low

Intervention not reported

Quality of life (QoL) We reported this outcome narratively in this review. Here, long‐term results (i.e., at the end of treatment) are presented. In the comparison PAZ versus SUN, QoL was measured using FACIT‐F (score range 0‐52; higher scores rep... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Salicylic acid vs tretinoin

Quality of life AQOL (long term: treatment duration > 8 weeks) · participants with acne

1 finding from 1 review

Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Very low

Intervention not reported

Quality of life Different QoL scales · patients with chronic hepatitis C

1 finding from 1 review

Aminoadamantanes for chronic hepatitis C 2014 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1181 participants
Very low